Jazz Pharmaceuticals, Chimerix HSR waiting period expired on March 31
MLex Summary: Jazz Pharmaceuticals and Chimerix saw the Hart-Scott-Rodino Act waiting period expire for their $935 million deal, the latter announced in a securities filing. The companies filed HSR paperwork on...To view the full article, register now.
Already a subscriber? Click here to view full article